Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Breast Cancer

  Free Subscription


19.02.2024

1 AJR Am J Roentgenol
4 Ann Surg Oncol
4 BMC Cancer
2 Br J Cancer
2 Breast Cancer
2 Breast Cancer Res
3 Breast Cancer Res Treat
1 Cancer
2 Cancer Epidemiol Biomarkers Prev
1 Cancer Lett
1 Cancer Res
3 Clin Breast Cancer
1 Clin Cancer Res
1 Discov Oncol
3 Eur Radiol
2 Exp Cell Res
1 Int J Radiat Oncol Biol Phys
4 J Clin Oncol
1 J Natl Cancer Inst
2 Lancet Oncol
1 Nature
1 Oncogene
1 Pathology
1 PLoS Med
3 PLoS One
1 Proc Natl Acad Sci U S A


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    AJR Am J Roentgenol

  1. PANIGRAHI B
    Editorial Comment: Utilization of Radiomics to Identify HER2-Low Breast Cancer.
    AJR Am J Roentgenol. 2024 Feb 14. doi: 10.2214/AJR.24.30953.
    PubMed        


    Ann Surg Oncol

  2. CORTINA CS, Lloren JI, Rogers C, Johnson MK, et al
    ASO Visual Abstract: Does Neoadjuvant Chemotherapy in Clinical T1-T2 N0 Triple-Negative Breast Cancer Increase the Extent of Axillary Surgery?
    Ann Surg Oncol. 2024 Feb 15. doi: 10.1245/s10434-024-15037.
    PubMed        

  3. SCHWARTZ T
    At the Speed of SOUND: The Pace of Change for Axillary Management in Breast Cancer.
    Ann Surg Oncol. 2024 Feb 12. doi: 10.1245/s10434-024-15010.
    PubMed        

  4. CHUNG AP, Dang CM, Karlan SR, Amersi FF, et al
    A Prospective Study of Sentinel Node Biopsy Omission in Women Age >/= 65 Years with ER+ Breast Cancer.
    Ann Surg Oncol. 2024 Feb 12. doi: 10.1245/s10434-024-15000.
    PubMed         Abstract available

  5. CORTINA CS, Rogers CC, Teshome M
    ASO Author Reflections: Neoadjuvant Systemic Therapy and Nodal Management in cT1-2 N0 Triple-Negative Breast Cancer.
    Ann Surg Oncol. 2024 Feb 10. doi: 10.1245/s10434-024-15020.
    PubMed        


    BMC Cancer

  6. SU MX, Lin HW, Nguyen HTH, Lin TC, et al
    Monitoring trends in the absolute lymphocyte count and the neutrophil-to-lymphocyte ratio in patients with breast cancer receiving eribulin.
    BMC Cancer. 2024;24:195.
    PubMed         Abstract available

  7. LABEDZ N, Anisiewicz A, Stachowicz-Suhs M, Banach J, et al
    Dual effect of vitamin D(3) on breast cancer-associated fibroblasts.
    BMC Cancer. 2024;24:209.
    PubMed         Abstract available

  8. ZHANG Y, Song M, Yang Z, Huang X, et al
    Healthy lifestyles, systemic inflammation and breast cancer risk: a mediation analysis.
    BMC Cancer. 2024;24:208.
    PubMed         Abstract available

  9. HUANG X, Yu Y, Luo S, Fu W, et al
    Correction: The value of oral selective estrogen receptor degraders in patients with HR-positive, HER2-negative advanced breast cancer after progression on >/= 1 line of endocrine therapy: systematic review and meta-analysis.
    BMC Cancer. 2024;24:205.
    PubMed        


    Br J Cancer

  10. SONG X, Fang C, Dai Y, Sun Y, et al
    Cyclin-dependent kinase 7 (CDK7) inhibitors as a novel therapeutic strategy for different molecular types of breast cancer.
    Br J Cancer. 2024 Feb 14. doi: 10.1038/s41416-024-02589.
    PubMed         Abstract available

  11. YE HS, Zhou D, Li H, Lv J, et al
    Organoid forming potential as complementary parameter for accurate evaluation of breast cancer neoadjuvant therapeutic efficacy.
    Br J Cancer. 2024 Feb 10. doi: 10.1038/s41416-024-02595.
    PubMed         Abstract available


    Breast Cancer

  12. HACKING SM, Windsor G, Cooper R, Jiao Z, et al
    A novel approach correlating pathologic complete response with digital pathology and radiomics in triple-negative breast cancer.
    Breast Cancer. 2024 Feb 13. doi: 10.1007/s12282-024-01544.
    PubMed         Abstract available

  13. SATO K, Fuchikami H, Takeda N, Natsume N, et al
    Preliminary report on ultrashort perioperative partial-breast irradiation with multicatheter interstitial brachytherapy for early-stage breast cancer.
    Breast Cancer. 2024 Feb 15. doi: 10.1007/s12282-024-01546.
    PubMed         Abstract available


    Breast Cancer Res

  14. WANG M, Du S, Gao S, Zhao R, et al
    MRI-based tumor shrinkage patterns after early neoadjuvant therapy in breast cancer: correlation with molecular subtypes and pathological response after therapy.
    Breast Cancer Res. 2024;26:26.
    PubMed         Abstract available

  15. LI JK, Jin ZY, Xu YJ, Fu NQ, et al
    Contrast-enhanced ultrasound to predict malignant upgrading of atypical ductal hyperplasia.
    Breast Cancer Res. 2024;26:27.
    PubMed         Abstract available


    Breast Cancer Res Treat

  16. MUTAI R, Kuchuk I, Goldshtein A, Yerushalmi R, et al
    The impact of germline BRCA pathogenic variants in locally advanced, triple negative breast cancer treated with platinum-based neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2024 Feb 12. doi: 10.1007/s10549-024-07247.
    PubMed         Abstract available

  17. GUPTA S, Sinha Gupta S, De A, Banerjee R, et al
    Socio-cultural and financial issues against breast cancer screening behaviour among eligible Indian women: evidence for action.
    Breast Cancer Res Treat. 2024 Feb 12. doi: 10.1007/s10549-024-07244.
    PubMed         Abstract available

  18. GAO L, Medford A, Spring L, Bar Y, et al
    Searching for the "Holy Grail" of breast cancer recurrence risk: a narrative review of the hunt for a better biomarker and the promise of circulating tumor DNA (ctDNA).
    Breast Cancer Res Treat. 2024 Feb 15. doi: 10.1007/s10549-024-07253.
    PubMed         Abstract available


    Cancer

  19. LI X, Luo S, Fu W, Huang M, et al
    Discovery of a proliferation essential gene signature and actin-like 6A as potential biomarkers for predicting prognosis and neoadjuvant chemotherapy response in triple-positive breast cancer.
    Cancer. 2024 Feb 15. doi: 10.1002/cncr.35228.
    PubMed         Abstract available


    Cancer Epidemiol Biomarkers Prev

  20. UONG SP, Torres JM, Alexeeff SE, Morey BN, et al
    Differences in Smoking Behavior by Nativity, Race/Ethnicity, and Education Among Women Diagnosed with Breast Cancer.
    Cancer Epidemiol Biomarkers Prev. 2024.
    PubMed         Abstract available

  21. ANDERSEN HH, Bojesen SE, Johansen JS, Ejlertsen B, et al
    Prognostic Value of Pre-treatment Plasma C-Reactive Protein in Patients with Early-Stage Breast Cancer.
    Cancer Epidemiol Biomarkers Prev. 2024.
    PubMed         Abstract available


    Cancer Lett

  22. XIONG H, Zhai Y, Meng Y, Wu Z, et al
    Acidosis activates breast cancer ferroptosis through ZFAND5/SLC3A2 signaling axis and elicits M1 macrophage polarization.
    Cancer Lett. 2024 Feb 13:216732. doi: 10.1016/j.canlet.2024.216732.
    PubMed         Abstract available


    Cancer Res

  23. YAN L, Wu M, Wang T, Yuan H, et al
    Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming that Drives Immune Evasion.
    Cancer Res. 2024 Feb 9. doi: 10.1158/0008-5472.CAN-23-2390.
    PubMed         Abstract available


    Clin Breast Cancer

  24. ZHANG C, Wang J, Wang H, Li J, et al
    Interference of the Circular RNA Sperm Antigen With Calponin Homology and Coiled-Coil Domains 1 Suppresses Growth and Promotes Apoptosis of Breast Cancer Cells Partially Through Targeting miR-1236-3p/Chromobox 8 Pathway.
    Clin Breast Cancer. 2023 Dec 2:S1526-8209(23)00304.
    PubMed         Abstract available

  25. KESKINKILIC M, Sacks R
    Antibody-Drug Conjugates in Triple Negative Breast Cancer.
    Clin Breast Cancer. 2024 Jan 20:S1526-8209(24)00008.
    PubMed         Abstract available

  26. MOKBEL K
    Elucidating Axillary Soft Tissue Involvement in Breast Cancer: Unveiling Metastatic Mechanisms and Therapeutic Perspectives.
    Clin Breast Cancer. 2024 Jan 29:S1526-8209(24)00024.
    PubMed         Abstract available


    Clin Cancer Res

  27. BARTLETT JMS, Xu K, Wong J, Pond G, et al
    Validation of the prognostic performance of Breast Cancer Index (BCI) in hormone receptor-positive (HR+) postmenopausal breast cancer patients in the TEAM trial.
    Clin Cancer Res. 2024 Feb 12. doi: 10.1158/1078-0432.CCR-23-2436.
    PubMed         Abstract available


    Discov Oncol

  28. LI F, Yang Y, Zhang X, Yu J, et al
    A novel prognostic model of breast cancer based on cuproptosis-related lncRNAs.
    Discov Oncol. 2024;15:35.
    PubMed         Abstract available


    Eur Radiol

  29. PARTRIDGE GJW, Taib AG, Phillips P, James JJ, et al
    Take a break: should breaks be enforced during digital breast tomosynthesis reading sessions?
    Eur Radiol. 2024;34:1388-1398.
    PubMed         Abstract available

  30. WANG Q, Lin Y, Ding C, Guan W, et al
    Multi-modality radiomics model predicts axillary lymph node metastasis of breast cancer using MRI and mammography.
    Eur Radiol. 2024 Feb 10. doi: 10.1007/s00330-024-10638.
    PubMed         Abstract available

  31. ZHENG S, Yang Z, Du G, Zhang Y, et al
    Discrimination between HER2-overexpressing, -low-expressing, and -zero-expressing statuses in breast cancer using multiparametric MRI-based radiomics.
    Eur Radiol. 2024 Feb 16. doi: 10.1007/s00330-024-10641.
    PubMed         Abstract available


    Exp Cell Res

  32. LI Y, Wei D, Chen Z, Chen Y, et al
    RBM10 regulates the tumorigenic potential of human cancer cells by modulating PPM1B and YBX1 activities.
    Exp Cell Res. 2024;435:113932.
    PubMed         Abstract available

  33. XU W, Goreczny GJ, Forsythe I, Brennan G, et al
    Hic-5 regulates extracellular matrix-associated gene expression and cytokine secretion in cancer associated fibroblasts.
    Exp Cell Res. 2024;435:113930.
    PubMed         Abstract available


    Int J Radiat Oncol Biol Phys

  34. YASHAYAEVA A, Dahn H, Svatos M, Zhan K, et al
    A Prospective Study Demonstrating Early Prediction of Skin Toxicity From Radiation Therapy Using Radiomic Features From Optical and Infrared Images.
    Int J Radiat Oncol Biol Phys. 2024;118:839-852.
    PubMed         Abstract available


    J Clin Oncol

  35. MCGRADY ME, Willard VW, Williams AM, Brinkman TM, et al
    Psychological Outcomes in Adolescent and Young Adult Cancer Survivors.
    J Clin Oncol. 2024;42:707-716.
    PubMed         Abstract available

  36. GEYER CE JR, Blum JL, Yothers G, Asmar L, et al
    Long-Term Follow-Up of the Anthracyclines in Early Breast Cancer Trials (USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 [NRG Oncology]).
    J Clin Oncol. 2024 Feb 9:JCO2301428. doi: 10.1200/JCO.23.01428.
    PubMed         Abstract available

  37. NEPPELENBROEK SIM, Geurts YM, Aleman BMP, Lugtenburg PJ, et al
    Doxorubicin Exposure and Breast Cancer Risk in Survivors of Adolescent and Adult Hodgkin Lymphoma.
    J Clin Oncol. 2024 Feb 15:JCO2301386. doi: 10.1200/JCO.23.01386.
    PubMed         Abstract available

  38. CHEN JC, Elsaid MI, Handley D, Plascak JJ, et al
    Association Between Neighborhood Opportunity, Allostatic Load, and All-Cause Mortality in Patients With Breast Cancer.
    J Clin Oncol. 2024 Feb 16:JCO2300907. doi: 10.1200/JCO.23.00907.
    PubMed         Abstract available


    J Natl Cancer Inst

  39. KERLIKOWSKE K, Zhu W, Su YR, Sprague BL, et al
    Supplemental magnetic resonance imaging plus mammography compared with magnetic resonance imaging or mammography by extent of breast density.
    J Natl Cancer Inst. 2024;116:249-257.
    PubMed         Abstract available


    Lancet Oncol

  40. PALMIERI C, Linden H, Birrell SN, Wheelwright S, et al
    Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multin
    Lancet Oncol. 2024 Feb 8:S1470-2045(24)00004.
    PubMed         Abstract available

  41. CHEN N, Nanda R
    Androgen receptor agonism in advanced oestrogen receptor-positive breast cancer.
    Lancet Oncol. 2024 Feb 8:S1470-2045(24)00080.
    PubMed        


    Nature

  42. ANDRE F, Rassy E, Marabelle A, Michiels S, et al
    Forget lung, breast or prostate cancer: why tumour naming needs to change.
    Nature. 2024;626:26-29.
    PubMed        


    Oncogene

  43. VENTURUTTI L, Romero LV, Urtreger AJ, Chervo MF, et al
    Correction: Stat3 regulates ErbB-2 expression and co-opts ErbB-2 nuclear function to induce miR-21 expression, PDCD4 downregulation and breast cancer metastasis.
    Oncogene. 2024 Feb 14. doi: 10.1038/s41388-024-02961.
    PubMed        


    Pathology

  44. BAEZ-NAVARRO X, van Bockstal MR, Jager A, van Deurzen CHM, et al
    HER2-low breast cancer and response to neoadjuvant chemotherapy: a population-based cohort study.
    Pathology. 2024 Jan 18:S0031-3025(24)00007-2. doi: 10.1016/j.pathol.2023.
    PubMed         Abstract available


    PLoS Med

  45. SELLEM L, Srour B, Javaux G, Chazelas E, et al
    Food additive emulsifiers and cancer risk: Results from the French prospective NutriNet-Sante cohort.
    PLoS Med. 2024;21:e1004338.
    PubMed         Abstract available


    PLoS One

  46. PUVVULA PK, Moon AM
    Discovery and characterization of anti-cancer peptides from a random peptide library.
    PLoS One. 2024;19:e0293072.
    PubMed         Abstract available

  47. RAGHURAM GV, Pal K, Sriram G, Khan A, et al
    Therapeutic interventions on human breast cancer xenografts promote systemic dissemination of oncogenes.
    PLoS One. 2024;19:e0298042.
    PubMed         Abstract available

  48. SVENDSEN SMS, Pedersen DC, Jensen BW, Aarestrup J, et al
    Early life body size and puberty markers as predictors of breast cancer risk later in life: A neural network analysis.
    PLoS One. 2024;19:e0296835.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  49. ZIKRY TM, Wolff SC, Ranek JS, Davis HM, et al
    Cell cycle plasticity underlies fractional resistance to palbociclib in ER+/HER2- breast tumor cells.
    Proc Natl Acad Sci U S A. 2024;121:e2309261121.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.